Aurobindo Pharma Ltd
NSE:AUROPHARMA
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Price:
1 262.45
INR
0.65%
Market Cap:
733.2B
INR
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
AUROPHARMA Alert
Aurobindo Pharma Ltd
1262.45
+8.10 (+0.65%)
| 52 Week Range |
989.8
1 568.05
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Aurobindo Pharma Ltd
Balance Sheet
Balance Sheet Decomposition
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd
| Current Assets | 242.1B |
| Cash & Short-Term Investments | 65.9B |
| Receivables | 48.4B |
| Other Current Assets | 127.8B |
| Non-Current Assets | 208.7B |
| Long-Term Investments | 6.7B |
| PP&E | 142.8B |
| Intangibles | 40.8B |
| Other Non-Current Assets | 18.3B |
| Current Liabilities | 122B |
| Accounts Payable | 44.5B |
| Other Current Liabilities | 77.4B |
| Non-Current Liabilities | 30.3B |
| Long-Term Debt | 23.9B |
| Other Non-Current Liabilities | 6.4B |
Balance Sheet
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd
Currency: INR
| Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
4 399
|
7 890
|
4 878
|
12 141
|
18 837
|
27 637
|
53 735
|
41 625
|
43 963
|
33 935
|
|
| Cash |
4 245
|
7 596
|
4 649
|
11 824
|
16 246
|
26 365
|
53 728
|
35 328
|
16 666
|
12 826
|
|
| Cash Equivalents |
154
|
294
|
229
|
317
|
2 591
|
1 272
|
7
|
6 297
|
27 297
|
21 109
|
|
| Short-Term Investments |
267
|
113
|
180
|
450
|
692
|
704
|
2 477
|
3 951
|
18 364
|
29 329
|
|
| Total Receivables |
36 937
|
46 574
|
35 419
|
50 575
|
61 231
|
58 705
|
50 594
|
58 889
|
66 871
|
76 258
|
|
| Accounts Receivables |
35 372
|
46 067
|
27 653
|
30 802
|
34 138
|
43 152
|
35 033
|
40 123
|
46 535
|
50 364
|
|
| Other Receivables |
1 565
|
507
|
7 766
|
19 773
|
27 093
|
15 553
|
15 561
|
18 766
|
20 336
|
25 894
|
|
| Inventory |
35 997
|
40 561
|
43 305
|
58 584
|
72 456
|
76 999
|
90 266
|
75 539
|
85 112
|
98 082
|
|
| Other Current Assets |
6 196
|
7 807
|
8 279
|
33
|
107
|
81
|
1 163
|
1 223
|
1 146
|
4 452
|
|
| Total Current Assets |
83 794
|
102 944
|
92 062
|
121 782
|
153 323
|
164 125
|
198 235
|
181 227
|
215 457
|
242 056
|
|
| PP&E Net |
31 986
|
42 163
|
53 204
|
61 361
|
70 356
|
81 166
|
93 155
|
106 660
|
124 918
|
142 849
|
|
| PP&E Gross |
0
|
42 163
|
53 204
|
61 361
|
70 356
|
81 166
|
93 155
|
106 660
|
124 918
|
142 849
|
|
| Accumulated Depreciation |
0
|
3 455
|
7 168
|
11 843
|
17 347
|
24 827
|
31 457
|
38 680
|
55 594
|
63 727
|
|
| Intangible Assets |
3 347
|
4 052
|
5 652
|
11 511
|
22 752
|
23 498
|
26 907
|
31 379
|
33 259
|
34 815
|
|
| Goodwill |
3 885
|
4 063
|
4 063
|
8 166
|
8 325
|
9 159
|
4 289
|
4 754
|
5 961
|
5 952
|
|
| Note Receivable |
55
|
55
|
2 824
|
3 475
|
4 318
|
4 094
|
7 012
|
6 042
|
7 065
|
8 164
|
|
| Long-Term Investments |
1 030
|
1 765
|
2 459
|
3 115
|
3 602
|
5 547
|
4 312
|
6 183
|
3 917
|
3 217
|
|
| Other Long-Term Assets |
4 027
|
4 161
|
2 231
|
1 602
|
1 868
|
1 687
|
4 630
|
2 972
|
8 324
|
13 664
|
|
| Other Assets |
3 885
|
4 063
|
4 063
|
8 166
|
8 325
|
9 159
|
4 289
|
4 754
|
5 961
|
5 952
|
|
| Total Assets |
128 124
N/A
|
159 202
+24%
|
162 494
+2%
|
211 010
+30%
|
264 544
+25%
|
289 277
+9%
|
338 540
+17%
|
339 217
+0%
|
398 900
+18%
|
450 715
+13%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
20 392
|
24 570
|
21 547
|
23 729
|
25 522
|
25 761
|
27 947
|
27 031
|
38 713
|
44 542
|
|
| Accrued Liabilities |
87
|
45
|
523
|
1 105
|
1 322
|
904
|
903
|
1 626
|
2 076
|
3 463
|
|
| Short-Term Debt |
24 971
|
36 727
|
29 027
|
40 313
|
65 575
|
54 223
|
48 027
|
21 236
|
41 647
|
40 781
|
|
| Current Portion of Long-Term Debt |
5 875
|
6 256
|
2 800
|
2 874
|
2 293
|
2 506
|
1 006
|
3 198
|
1 810
|
1 821
|
|
| Other Current Liabilities |
9 489
|
10 804
|
12 159
|
18 638
|
25 494
|
30 453
|
28 768
|
28 470
|
30 691
|
31 385
|
|
| Total Current Liabilities |
60 814
|
78 402
|
66 056
|
86 659
|
120 206
|
113 846
|
106 652
|
81 560
|
114 938
|
121 991
|
|
| Long-Term Debt |
13 111
|
7 428
|
1 814
|
4 512
|
1 800
|
2 644
|
4 887
|
5 678
|
9 405
|
23 874
|
|
| Deferred Income Tax |
2
|
240
|
493
|
2 353
|
2 813
|
2 917
|
5 746
|
4 110
|
3 896
|
3 566
|
|
| Minority Interest |
98
|
26
|
21
|
18
|
16
|
1
|
9
|
19
|
120
|
80
|
|
| Other Liabilities |
242
|
234
|
391
|
664
|
802
|
1 622
|
1 966
|
2 129
|
2 143
|
2 776
|
|
| Total Liabilities |
74 267
N/A
|
86 329
+16%
|
68 775
-20%
|
94 206
+37%
|
125 636
+33%
|
121 031
-4%
|
119 241
-1%
|
93 457
-22%
|
130 501
+40%
|
152 287
+17%
|
|
| Equity | |||||||||||
| Common Stock |
292
|
585
|
586
|
586
|
586
|
586
|
586
|
586
|
586
|
586
|
|
| Retained Earnings |
49 294
|
67 928
|
89 571
|
111 158
|
133 303
|
159 465
|
210 408
|
234 230
|
249 573
|
278 483
|
|
| Additional Paid In Capital |
4 309
|
4 097
|
4 173
|
4 176
|
4 176
|
4 179
|
4 179
|
4 179
|
4 179
|
4 179
|
|
| Other Equity |
38
|
264
|
611
|
885
|
843
|
4 017
|
4 126
|
6 765
|
14 061
|
15 180
|
|
| Total Equity |
53 857
N/A
|
72 873
+35%
|
93 719
+29%
|
116 804
+25%
|
138 908
+19%
|
168 247
+21%
|
219 299
+30%
|
245 760
+12%
|
268 399
+9%
|
298 428
+11%
|
|
| Total Liabilities & Equity |
128 124
N/A
|
159 202
+24%
|
162 494
+2%
|
211 010
+30%
|
264 544
+25%
|
289 277
+9%
|
338 540
+17%
|
339 217
+0%
|
398 900
+18%
|
450 715
+13%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
584
|
585
|
586
|
586
|
586
|
586
|
586
|
586
|
586
|
586
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
